MCID: SBC004
MIFTS: 25

Subacute Myeloid Leukemia

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Subacute Myeloid Leukemia

MalaCards integrated aliases for Subacute Myeloid Leukemia:

Name: Subacute Myeloid Leukemia 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:8747
SNOMED-CT 68 95278004
UMLS 73 C0153889

Summaries for Subacute Myeloid Leukemia

MalaCards based summary : Subacute Myeloid Leukemia is related to myeloid leukemia and leukemia, acute myeloid. An important gene associated with Subacute Myeloid Leukemia is TET2 (Tet Methylcytosine Dioxygenase 2), and among its related pathways/superpathways are CNTF Signaling and Tyrosine Kinases / Adaptors. The drugs Cytarabine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotype is neoplasm.

Related Diseases for Subacute Myeloid Leukemia

Graphical network of the top 20 diseases related to Subacute Myeloid Leukemia:



Diseases related to Subacute Myeloid Leukemia

Symptoms & Phenotypes for Subacute Myeloid Leukemia

MGI Mouse Phenotypes related to Subacute Myeloid Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.8 FLT3 JAK2 TET2

Drugs & Therapeutics for Subacute Myeloid Leukemia

Drugs for Subacute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 303)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
3
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 135968-09-1
4
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
5
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
6
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
7
Idarubicin Approved Phase 3 58957-92-9 42890
8
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
9
Decitabine Approved, Investigational Phase 3,Phase 1 2353-33-5 451668
10
Azacitidine Approved, Investigational Phase 3,Phase 1 320-67-2 9444
11
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
12
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
13
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
14
Acyclovir Approved Phase 3 59277-89-3 2022
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Daunorubicin Approved Phase 3 20830-81-3 30323
17
Mitoxantrone Approved, Investigational Phase 3,Phase 2 65271-80-9 4212
18
Thioguanine Approved Phase 3 154-42-7 2723601
19
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
20
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
21
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
22
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
23
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
24 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Not Applicable 979-32-8
25
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
26
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
27
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
28
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
29
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
30 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
31 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
32 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
34 6-Mercaptopurine Phase 3
35 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
40 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
42 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
43 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
44 interferons Phase 3,Phase 2
45 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
47 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Interferon-alpha Phase 3,Phase 2
49 Anesthetics, Dissociative Phase 3
50 Anesthetics, General Phase 3

Interventional clinical trials:

(show top 50) (show all 202)
# Name Status NCT ID Phase Drugs
1 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
2 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
5 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
6 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
7 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
8 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
9 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
15 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
16 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
17 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
18 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
19 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
20 Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Unknown status NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
21 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
22 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
23 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
24 Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia Completed NCT00079313 Phase 2 Imatinib
25 Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Completed NCT00002598 Phase 2 cyclophosphamide;cytarabine;etoposide;methotrexate;mitoxantrone hydrochloride
26 Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
27 Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00217386 Phase 2
28 Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma Completed NCT00002681 Phase 1, Phase 2
29 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
30 Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
31 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
32 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
33 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
34 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
35 Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
36 Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00052832 Phase 2
37 Cholecalciferol in Treating Patients With Myelodysplastic Syndrome Completed NCT00068276 Phase 2
38 Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
39 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
40 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
41 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
42 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
43 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
44 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
45 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
46 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
47 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
48 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
49 High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors Completed NCT00060255 Phase 2 busulfan;carboplatin;carmustine;cyclophosphamide;etoposide;melphalan;thiotepa
50 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2

Search NIH Clinical Center for Subacute Myeloid Leukemia

Genetic Tests for Subacute Myeloid Leukemia

Anatomical Context for Subacute Myeloid Leukemia

MalaCards organs/tissues related to Subacute Myeloid Leukemia:

41
Myeloid, Bone, Bone Marrow

Publications for Subacute Myeloid Leukemia

Articles related to Subacute Myeloid Leukemia:

# Title Authors Year
1
Possibility of the diagnosis of subacute myeloid leukemia for a group of patients with trisomy 8: a report of 34 cases. ( 15481445 )
2004
2
Acute myeloid leukemia M2B (subacute myeloid leukemia) in China. ( 9150353 )
1997
3
Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia. ( 6578393 )
1983
4
Subacute myeloid leukemia: a clinical review. ( 287373 )
1979

Variations for Subacute Myeloid Leukemia

Expression for Subacute Myeloid Leukemia

Search GEO for disease gene expression data for Subacute Myeloid Leukemia.

Pathways for Subacute Myeloid Leukemia

Pathways related to Subacute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.29 FLT3 JAK2
2 10.79 FLT3 JAK2

GO Terms for Subacute Myeloid Leukemia

Biological processes related to Subacute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin organization GO:0006325 9.4 JAK2 TET2
2 cytokine-mediated signaling pathway GO:0019221 9.37 FLT3 JAK2
3 MAPK cascade GO:0000165 9.32 FLT3 JAK2
4 peptidyl-tyrosine phosphorylation GO:0018108 9.26 FLT3 JAK2
5 protein autophosphorylation GO:0046777 9.16 FLT3 JAK2
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 8.96 FLT3 JAK2
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.62 FLT3 JAK2

Molecular functions related to Subacute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 8.96 FLT3 JAK2
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.62 FLT3 JAK2

Sources for Subacute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....